"My mother has Alzheimer's. Her doctors could have protected her brain."

Some mornings are good mornings.

She sits across from me on the terrace, coffee in both hands, watching the light come up over Lake Chapala. The bougainvillea is ridiculous in May, purple-pink and overgrown, and she notices it. She’ll say something funny. She’ll have an opinion about something. She’ll be herself, fully, for an hour.

Then some mornings she looks at me with this soft, searching look. She knows I’m her daughter. That recognition is still there, and I am grateful for it every single day. But the word for me, the specific word that is my name, is somewhere she can’t reach anymore.

She’s 83. She has Alzheimer’s. She lives in my guest house here in Ajijic with a full nursing team around her. She never took a single hormone.

I’ve been sitting with one question for two years, since I learned what the critical window actually is and what the research actually says about it. The question doesn’t go away.

Would her brain be different today if she had been given estrogen in 2002?

---

The window — and how medicine slammed it shut

In July 2002, the Women’s Health Initiative announced that hormone replacement therapy increased breast cancer risk, cardiovascular disease risk, and stroke risk. The announcement went everywhere. Headlines across every network, every newspaper. Doctors across the country stopped prescribing. Women already on HRT were told to stop. Women going to their doctors for help with menopause symptoms were told: too risky.

My mother was in her early 50s that year. She was having hot flashes. She wasn’t sleeping. She was going to her doctors and asking for help with the things women go to doctors for. Her doctors, like virtually every doctor in America that year, told her the same thing: too risky. Take nothing.

She was doing the right thing. She was advocating for herself. And medicine failed her.

Here’s what medicine knew but didn’t yet fully understand in 2002, and what the research has since made clear: estrogen’s neuroprotective effects are not a blanket benefit that applies at any age, any time after menopause. They are time-dependent. There is a window, roughly the first ten years after menopause, when the brain’s estrogen receptors are intact and responsive. Start estrogen in that window and it works. It supports neural metabolism, reduces amyloid accumulation, protects synaptic connections, and supports the cholinergic neurotransmitter system, which is the first system that Alzheimer’s damages.

Wait too long, and the window closes. The receptors downregulate. The architecture that estrogen was meant to maintain has already started to degrade. Starting estrogen after the window doesn’t just fail to protect the brain; in some studies it increases risk.

Timing, it turns out, is everything.

My mother was in the window in 2002. The window was open. She needed only a prescription. Her doctors, acting on a study they didn’t yet know was being applied to the wrong population at the wrong age, said no.

---

The science is no longer in dispute

The timing hypothesis — the idea that estrogen’s neuroprotective benefit is window-dependent — is not new science. It has been accumulating for two decades. What’s changed is the weight of evidence behind it.

Three meta-analyses covering large populations of women now show that hormone replacement therapy, when started within ten years of menopause, is associated with a 34% decreased risk of dementia and a 40% decreased risk of Alzheimer’s specifically. Those are not trivial numbers. Those are the kinds of numbers that change how medicine should be practiced.

The mechanism is not mysterious. Estrogen supports the metabolic machinery that neurons run on. It promotes the clearance of amyloid-beta, the protein that aggregates into the plaques that define Alzheimer’s pathology. It protects the cholinergic neurons in the basal forebrain, which are the neurons that project throughout the cortex and hippocampus and enable memory encoding. Alzheimer’s disease attacks the cholinergic system first and worst. Estrogen is one of its known protectors. Remove the protection during the years when the system is actively maintaining itself and you remove the defense at exactly the moment it matters.

Now — you may have heard the other side of this. The Women’s Health Initiative Memory Study, WHIMS, was an add-on to the original WHI. It found that hormone therapy actually increased dementia risk. That finding went everywhere, the same way the 2002 headline did.

Here is what WHIMS actually enrolled: women with an average age of 71. That is not the critical window. That is well past it. In a significant portion of the WHIMS population, the window had been closed for fifteen to twenty years. You cannot study the neuroprotective effect of a time-limited intervention by enrolling people who have already passed the time limit, and then apply that result to women who are within it.

This is the same error as the 2002 WHI itself. Enroll women outside the critical population. Find a negative result. Apply it to women inside the critical population. Generate a generation of harm.

The researchers who designed the original WHI mostly acknowledged this limitation in subsequent years. The WHIMS result and the window hypothesis are not actually in conflict. They describe different things happening at different times. The harm of the WHIMS framing was that it was presented as if the timing didn’t matter. It matters enormously.

---

My own position on this timeline

I carry two copies of the APOE4 gene. Homozygous APOE4 is the highest genetic risk profile for Alzheimer’s that exists in the general population, roughly ten to fifteen times the baseline population risk, possibly higher per some estimates.

My mother has Alzheimer’s. My aunt died of Alzheimer’s in 2022. I watch this disease up close. I have watched it take my mother’s words, her recent memories, her ability to hold the thread of a conversation. I know what it looks like in the early stages, the middle stages. I know what is coming.

And I know that I am sitting on the same biological timeline, with the same genetic profile, at 57. Which means, if the timing hypothesis is correct, I am either still inside or at the very edge of my own critical window.

I started HRT. I am not stopping.

This is not a casual decision. This is not symptom management. I take estrogen because my mother never did, because I understand what the cholinergic system does, because I know what APOE4 means for amyloid accumulation, and because the research now says that the window is real and that it closes. I will not miss mine.

I am not my mother’s doctor and I cannot rewrite 2002. But I can be here, in 2026, making different choices with the same genes and the same family history, because the science has finally been said loudly enough that I could hear it.

---

What “she was never given the option” actually means

I want to be clear about something, because I’ve thought about this a lot.

My mother did not make a bad choice. She made no choice at all. She asked her doctors for help and was told the answer was no. She was a woman in her early 50s in 2002, symptomatic, doing exactly what she was supposed to do, going to medical professionals and trusting their guidance.

What those doctors were doing was practicing medicine according to the best information they had, which had just been upended by a major federal study. I do not blame her doctors as people. I am furious at a system that rushed to apply a study’s conclusions to a population the study never enrolled, that let a 2002 headline become a 2005 guideline and a 2010 practice norm and a 2015 doctor’s reflex, without doing the work to understand the timing.

The 2002 WHI enrolled women whose average age was 63. The signal for harm came from an older population. The clinical response was to stop prescribing to women in their early 50s, who were inside a different biological window entirely. The guidance was wrong. It was applied to the wrong population, for a duration longer than the study ran, citing risks that were artifacts of a flawed study design and a mismatched age group.

That error cost women their windows. My mother’s window. Millions of windows. And if the timing hypothesis is correct, some of those windows led to Alzheimer’s diagnoses that didn’t have to happen.

That is not a dramatic claim. That is what the evidence says.

---

February 2026, and what the FDA finally did

In February 2026, the FDA removed the black box warnings from systemic hormone replacement therapy products. The new label language explicitly states that women who start HRT within ten years of menopause may reduce their Alzheimer’s risk by 35%, cardiovascular risk by 50%, and bone fracture risk by 50 to 60%.

Twenty-three years after my mother stood in a doctor’s office and was told the words “too risky.”

The information was there, building in the literature, for most of those years. The WHIMS design flaw was identified and published. The timing hypothesis was developed, tested, and replicated. Meta-analyses accumulated. The Alzheimer’s numbers got harder to ignore.

And in February 2026, the FDA label caught up with what the science had been saying for a decade.

My mother is 83. The label change does not reach her. Her window has been closed for twenty years. The question I keep asking myself is not answerable, and I know that. I cannot know what her brain would look like today if her doctors in 2002 had said yes instead of no. I cannot know if she would still be the full version of herself. I can only know what the population-level data says, and what it says is that her odds would have been different.

---

The window is real. It closes. Don’t miss yours.

I started every one of these articles with a line about my mother. Some mornings on the terrace, some detail about life here in Ajijic, a little signal about who I’m writing from and why.

This is the piece where I tell you the full story. Because you deserve to understand why someone builds a newsletter about menopause science and posts articles into the world every week. It is not because I have a platform and need content. It is because I have an APOE4 homozygous genotype and a mother who can’t remember my name, and because two years ago I started reading the research and found out that this didn’t have to go this way.

It did not have to go this way.

If you are in your late 40s or early 50s, or if you went through menopause in the last ten years and have never had a serious conversation about hormone therapy and brain protection, I am asking you to take this seriously.

The window is real. The ten years post-menopause when estrogen protects neural metabolism and slows amyloid accumulation and supports the cholinergic system that Alzheimer’s destroys first. That window is real, and it closes, and once it closes the neuroprotective benefit is gone and may reverse.

You cannot get the window back.

What you can do is find a menopause specialist who understands the timing hypothesis and can tell you where you are in your own window. Not a general practitioner who learned “lowest dose, shortest time” in residency and never updated. A specialist. The Menopause Society (formerly NAMS) has a provider finder at menopause.org. Use it. The Newson Health clinic in the UK does telehealth internationally. Midi Health covers the US. The options have expanded.

I could not give my mother her window back. I could not reach back to 2002 and put a different doctor in that office. I can only do what I am doing now, which is make sure that the women reading this in 2026 understand what the science says, clearly and without the hedging that let this go on for twenty-three years.

Estrogen, started at the right time, protects the brain. The window closes. Don’t wait.

---

Annette Thompson is 57, the founder of adoption.com, and a menopause advocate writing about evidence-based women’s health.

---

Sources: Brinton RD, Yao J, Yin F, et al. “Perimenopause as a neurological transition state.” Nature Reviews Endocrinology, 2015 | Shumaker SA et al. “Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women” (WHIMS). JAMA, 2003 (PMID 12771112) | Henderson VW. “Alzheimer’s disease: review of hormone therapy trials and implications for treatment and prevention after menopause.” J Steroid Biochem Mol Biol, 2014 (PMID 23707452) | Maki PM, Henderson VW. “Hormone therapy, dementia, and cognition: the Women’s Health Initiative 10 years on.” Climacteric, 2012 | Collaborative Group on Hormonal Factors in Breast Cancer. “Type and timing of menopausal hormone therapy and breast cancer risk.” Lancet, 2019 | FDA HRT label update, February 2026 | Menopause Society (NAMS) 2023 Position Statement on Hormone Therapy